KYMR on XNAS, Health Care, Kymera Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue rose 134% to $102.2M, but the company lost $349.4M over 12 months.
BadFree cash outflow $288.9M over 12 months, against $971.2M cash
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $132.0M.
31 Dec 2021RevenueNet incomeNet losstallest bar $132.0M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$0
-$132.0M
30 Jun 2026
$65.0M
-$61.2M
31 Mar 2026
$34.4M
-$69.2M
31 Dec 2025
$2.9M
-$87.0M
30 Sep 2025
$2.8M
-$82.2M
30 Jun 2025
$11.5M
-$76.6M
31 Mar 2025
$22.1M
-$65.6M
31 Dec 2024
$7.4M
-$70.8M
30 Sep 2024
$3.7M
-$62.5M
30 Jun 2024
$25.6M
-$42.1M
31 Mar 2024
$10.3M
-$48.6M
31 Dec 2023
–
-$14.4M
30 Sep 2023
$4.7M
-$52.9M
30 Jun 2023
$16.5M
-$38.8M
31 Mar 2023
$9.5M
-$40.9M
31 Dec 2022
$16.1M
-$34.9M
30 Sep 2022
$9.6M
-$43.0M
30 Jun 2022
$11.5M
-$40.3M
31 Mar 2022
$9.6M
-$36.7M
31 Dec 2021
$15.3M
-$33.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$102.2M
$43.7M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+134%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$349.4M
-$295.1M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$3.63
-$3.60
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
0.0%
0.0%
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-396%
-760%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-342%
-675%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-27.3%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$288.9M
-$230.2M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$971.2M
$505.7M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$18.91
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
96.3
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
6.1
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$4.2M
bought $0, sold $4.2M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+10%
299 13F filers vs 271
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
98.9M shares held by 13F filers (30 Sep 2026) of 85.4M outstanding (23 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
9.8%
8.4M shares sold short (30 Oct 2026) of 85.4M outstanding (23 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
10.5
8.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-8.4%
9.2M shares sold short in the report before, 8.4M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
42%
42% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 69%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
21
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
36
36 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
12×
36 articles in the last 7 days; its usual week has 3.
Price $115.31 on 20 Nov 2026, +78% over 12 months (12-month range $64.27 to $138.86)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $292.5M in the last 12 months (the 12 months before: $27.8M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, 0% on the 12 months before.Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.Capital spending per quarter. Capital spending $315K in the latest quarter, +74% on a year earlier.Institutional holders (13F filers). 299 13F filers reported holding it in the latest 13F quarter, +47% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $15.3M, +19% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $9.6M, -49% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $11.5M, -38% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $9.6M, -53% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $16.1M, +5.7% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $9.5M, -1.6% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $16.5M, +43% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $4.7M, -50% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Mar 2024: $10.3M, +8.7% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $25.6M, +55% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $3.7M, -21% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $7.4M; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $22.1M, +115% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $11.5M, -55% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $2.8M, -26% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $2.9M, -61% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $34.4M, +55% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $65.0M, +466% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $501K, -65% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $482K, +194% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $735K, +17% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $1.2M, +307% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $373K, -26% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $4.0M, +732% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $10.8M, +1365% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $8.1M, +548% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $11.6M, +3017% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $7.4M, +85% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $4.7M, -56% on a year earlier; public on 8 Aug 2024
Quarter ended 31 Dec 2024: $936K, -92% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $467K, -94% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $695K, -85% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $181K; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $106K, -89% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $434K, -7.1% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $473K, -32% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $315K, +74% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 116; public on 14 Feb 2022
31 Mar 2022 report: 119; public on 16 May 2022
30 Jun 2022 report: 96; public on 15 Aug 2022
30 Sep 2022 report: 115; public on 14 Nov 2022
31 Dec 2022 report: 109; public on 14 Feb 2023
31 Mar 2023 report: 121; public on 15 May 2023
30 Jun 2023 report: 121; public on 14 Aug 2023
30 Sep 2023 report: 111; public on 14 Nov 2023
31 Dec 2023 report: 126; public on 14 Feb 2024
31 Mar 2024 report: 155; public on 15 May 2024
30 Jun 2024 report: 148; public on 14 Aug 2024
30 Sep 2024 report: 172; public on 14 Nov 2024
31 Dec 2024 report: 176; public on 14 Feb 2025
31 Mar 2025 report: 167; public on 15 May 2025
30 Jun 2025 report: 204; public on 14 Aug 2025
30 Sep 2025 report: 204; public on 14 Nov 2025
31 Dec 2025 report: 247; public on 17 Feb 2026
31 Mar 2026 report: 251; public on 15 May 2026
30 Jun 2026 report: 271; public on 14 Aug 2026
30 Sep 2026 report: 299; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $128.5M (30 Sep 2026), 1.8× its normal quarter; higher than 100% of its own history.
Quarterly revenue change: reported revenue of $65.0M for the quarter ended 30 Jun 2026, 5.7× the same quarter last year Public on 6 Aug 2026.
21 open postings; careers site tracked since 20 Nov 2026. Most in Operations & administration 24%, Program & project management 19%, Legal, policy & compliance 10%, ML / AI 10%.
Two or more unrelated kinds of records unusual within 30 days
27 Feb 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials
Kymera Therapeutics(KYMR): saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year, while it spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year. Two unrelated kinds of activity within 7 days.
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2024
Financials: Quarterly capital spending jump, became public on 27 Feb 2024
The quarter ended 31 Dec 2023 against the 8 quarters before it.
this quarterearliernormal: 13.5See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2024
Kymera Therapeutics saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year.
This period
26 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.2
Same quarter last year
13
History used
1,187 days
the quarter ended 31 Dec 20238 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly capital spending jump became public on 27 Feb 2024
Kymera Therapeutics spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year.
This period
$11.6M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$990K
Typical spread (median absolute deviation)
$563K
How far from its usual level
+10.6
Same quarter last year
$373K
History used
1,461 days
the quarter ended 31 Dec 20238 earlier quartersnormal: $990K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
6 Aug 2026Financials change
reported revenue of $65.0M for the quarter ended 30 Jun 2026, 5.7× the same quarter last year.
Same quarter last year: $11.5M; its normal quarter is $9.4M.
See the evidence
This period
$65.0M (the quarter ended 30 Jun 2026)
Normal quarter (median of 8 earlier)
$9.4M
Typical spread (median absolute deviation)
$6.6M
How far from its usual level
+5.7
Same quarter last year
$11.5M
History used
2,465 days
the quarter ended 30 Jun 20268 earlier quartersnormal: $9.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $34.4M for the quarter ended 31 Mar 2026, 1.6× the same quarter last year.
Same quarter last year: $22.1M; its normal quarter is $8.8M.
See the evidence
This period
$34.4M (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
$8.8M
Typical spread (median absolute deviation)
$5.5M
How far from its usual level
+3.1
Same quarter last year
$22.1M
History used
2,374 days
the quarter ended 31 Mar 20268 earlier quartersnormal: $8.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 64 13F filers open a new position in the quarter ended 30 Jun 2025, 2.9× the same quarter last year.
Same quarter last year: 22; its normal quarter is 22.
See the evidence
This period
64 (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
22
Typical spread (median absolute deviation)
4.5
How far from its usual level
+6.3
Same quarter last year
22
History used
1,734 days
the quarter ended 30 Jun 20258 earlier quartersnormal: 22
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $25.6M for the quarter ended 30 Jun 2024, 1.6× the same quarter last year.
Same quarter last year: $16.5M; its normal quarter is $10.0M.
See the evidence
This period
$25.6M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$10.0M
Typical spread (median absolute deviation)
$1.0M
How far from its usual level
+10.3
Same quarter last year
$16.5M
History used
1,735 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $10.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
saw 38 13F filers open a new position in the quarter ended 31 Mar 2024, 2.9× the same quarter last year.
Same quarter last year: 13; its normal quarter is 13.5.
See the evidence
This period
38 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.2
Same quarter last year
13
History used
1,278 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year, while it spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year. Two unrelated kinds of activity within 7 days.
See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 14 Feb 2024
Kymera Therapeutics saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year.
This period
26 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.2
Same quarter last year
13
History used
1,187 days
the quarter ended 31 Dec 20238 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Financials: Quarterly capital spending jump became public on 27 Feb 2024
Kymera Therapeutics spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year.
This period
$11.6M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$990K
Typical spread (median absolute deviation)
$563K
How far from its usual level
+10.6
Same quarter last year
$373K
History used
1,461 days
the quarter ended 31 Dec 20238 earlier quartersnormal: $990K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
27 Feb 2024Financials change
spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year.
Same quarter last year: $373K; its normal quarter is $990K.
See the evidence
This period
$11.6M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$990K
Typical spread (median absolute deviation)
$563K
How far from its usual level
+10.6
Same quarter last year
$373K
History used
1,461 days
the quarter ended 31 Dec 20238 earlier quartersnormal: $990K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year.
Same quarter last year: 13; its normal quarter is 13.5.
See the evidence
This period
26 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.2
Same quarter last year
13
History used
1,187 days
the quarter ended 31 Dec 20238 earlier quartersnormal: 13.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
spent $8.1M on capital projects in the quarter ended 30 Sep 2023, 6.5× the same quarter last year.
Same quarter last year: $1.2M; its normal quarter is $618K.
See the evidence
This period
$8.1M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$618K
Typical spread (median absolute deviation)
$278K
How far from its usual level
+7.5
Same quarter last year
$1.2M
History used
1,369 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $618K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $10.8M on capital projects in the quarter ended 30 Jun 2023, 15× the same quarter last year.
Same quarter last year: $735K; its normal quarter is $564K.
See the evidence
This period
$10.8M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$564K
Typical spread (median absolute deviation)
$181K
How far from its usual level
+10.2
Same quarter last year
$735K
History used
1,277 days
the quarter ended 30 Jun 20238 earlier quartersnormal: $564K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 6.1M shares sold short in the 29 Jul 2022 report, 3.0× the same report last year.
Same report last year: 2.1M; its normal report is 2.2M.
See the evidence
This period
6.1M (the 29 Jul 2022 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
669K
How far from its usual level
+4.0
Same report last year
2.1M
History used
697 days
the 29 Jul 2022 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.4M shares sold short in the 15 Jul 2022 report, 3.3× the same report last year.
Same report last year: 1.9M; its normal report is 2.2M.
See the evidence
This period
6.4M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
651K
How far from its usual level
+4.4
Same report last year
1.9M
History used
683 days
the 15 Jul 2022 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.8M shares sold short in the 30 Jun 2022 report, 2.5× the same report last year.
Same report last year: 2.4M; its normal report is 2.1M.
See the evidence
This period
5.8M (the 30 Jun 2022 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
544K
How far from its usual level
+4.7
Same report last year
2.4M
History used
668 days
the 30 Jun 2022 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.0M shares sold short in the 15 Jun 2022 report, 2.8× the same report last year.
Same report last year: 1.8M; its normal report is 2.0M.
See the evidence
This period
5.0M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
443K
How far from its usual level
+4.5
Same report last year
1.8M
History used
653 days
the 15 Jun 2022 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.9M shares sold short in the 31 May 2022 report, 2.5× the same report last year.
Same report last year: 2.0M; its normal report is 2.0M.
See the evidence
This period
4.9M (the 31 May 2022 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
359K
How far from its usual level
+5.4
Same report last year
2.0M
History used
638 days
the 31 May 2022 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 62 entries; narrow the window or the kind of data to see older ones.
Not listed: 200 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001815442
Ticker
KYMR
Domain
kymeratx.com
Employer name
Kymera Therapeutics, Inc. (1 unverified)
Hq location
MA|WATERTOWN|02472 (1 unverified)
Name
ACTIVE/107610297.1, EX-21.1, Kymera Securities Corporation, Kymera Therapeutics, Inc. and 1 more
Wikidata
Q113503520
DOL H-1B labor condition applications and PERM certifications96 data points8 Feb 2021 to 27 Jul 2026
SEC Form 13F institutional holdings225 data points30 Sep 2020 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)104 records31 Jul 2020 to 29 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)456 data points31 Dec 2018 to 23 Oct 2026
SEC Form 4 insider transactions131 records, 380 data points19 Feb 2021 to 1 Oct 2026
FINRA short interest (twice monthly)443 data points31 Aug 2020 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)3142 data points21 Aug 2020 to 20 Nov 2026